Abstract: Disclosed are methods of using AMPK-activating compounds, for example, in the treatment of cancer and disorders of vascular flow. Also disclosed are biomarkers for AMPK and uses thereof, for example, in the diagnosis and treatment of AMPK-linked disorders. In certain embodiments, the AMPK-activating compounds have the structural formula wherein E, J, T, D1, D2, D3, the ring system denoted by “B”, T, R3, R4, w and x are as described herein.

Abstract: The invention comprises methods and cell lines for assaying APOBEC3G degradation and methods for identifying inhibitors of APOBEC3G degradation. The invention also provides methods of identifying inhibitors of HIV infection. The methods of the invention are useful for identifying inhibitors of viral infection, in particular, the methods of the invention are useful for treating retroviral infection.

Abstract: The invention comprises methods and cell lines for assaying APOBEC3G degradation and methods for identifying inhibitors of APOBEC3G degradation. The invention also provides methods of identifying inhibitors of HIV infection. The methods of the invention are useful for identifying inhibitors of viral infection, in particular, the methods of the invention are useful for treating retroviral infection.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, which are involved in modulation of cell cycle arrest.

Abstract: The present invention relates to methods of inhibiting replication of a retrovirus, such as human immunodeficiency virus (HIV), by inhibiting modulation of ubiquitylation of a host cell substrate protein, such as CEM15 of CD4, where ubiquitylation modulation is mediated by a retroviral protein, such as HIV Vif or Vpu. The invention also relates to screening methods for identifying agents that inhibit viral replication by inhibiting retroviral protein-mediated modulation of host cell ubiquitylation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding protein kinase C &zgr; (PKC-&zgr;), phospholipase C-&bgr;1 (PLC-&bgr;1), protein tyrosine kinase 2 (FAK), protein tyrosine kinase 2b (FAK2), casein kinase 2 (CK2), cMET tyrosine kinase (cMET), flap structure specific endonuclease 1 (FEN1), REV1 dCMP transferase (REV1), apurinic/apyrimidinic nuclease 1 (APE1), cyclin dependent kinase 3 (CDK3), PIM1 kinase (PIM1), cell division cycle 7 kinase (CDC7L1), cyclin dependent kinase 7 (CDK7), cytokine inducible kinase (CNK), potentially prenylated protein tyrosine phosphatase (PRL-3), serine threonine kinase 2 (STK2) or (NEK4), cyclin dependent serine threonine kinase (NKIAMRE), or histone acetylase (HBO1), which are involved in modulation of cell cycle arrest.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BAP-1, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of BAP-1; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE 11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE 11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.